Sentences with phrase «cell precursor leukemia»
Not exact matches
In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.
https://www.cnbc.com/
The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.
In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.
Researchers at University of California San Diego School of Medicine have now unraveled how pre-leukemic white blood cell precursors become leukemia stem cells.
Ultimately, this activity increases cellular regeneration, or self - renewal, turning white blood cell precursors into leukemia stem cells.
In 2014, the FDA approved Amgen's BLINCYTO ® (blinatumumab), the first BiTE ® therapy to receive FDA approval, for the treatment of Philadelphia chromosome - negative relapsed or refractory B - cell precursor acute lymphoblastic leukemia, a rare and rapidly progressing cancer of the blood and bone marrow.
Effects of the chemokine stromal cell - derived factor - 1 on the migration and localization of precursor - B acute lymphoblastic leukemia cells within bone marrow stromal layers.
Other CAR T - cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B - cell precursor acute lymphoblastic leukemia and axicabtagene ciloleucil (aci - cel; Yescarta) for adults with relapsed or refractory DLBCL.
A phase I / II trial of KTE - C19 (anti-CD19 CAR T cells) for pediatric and adolescent subjects with relapsed / refractory B - precursor acute lymphoblastic leukemia -LRB-
CpG stimulation of precursor B lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells towards a Th1 response.